

Sobha Sivaprasad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1893575/publications.pdf>

Version: 2024-02-01

380
papers

13,426
citations

25034

57
h-index

33894

99
g-index

399
all docs

399
docs citations

399
times ranked

12007
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. <i>Eye</i> , 2023, 37, 6-16.	2.1	18
2	Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration—the PINNACLE trial protocol. <i>Eye</i> , 2023, 37, 1275-1283.	2.1	9
3	Inter-rater reliability for diagnosis of geographic atrophy using spectral domain OCT in age-related macular degeneration. <i>Eye</i> , 2022, 36, 392-397.	2.1	10
4	Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. <i>Progress in Retinal and Eye Research</i> , 2022, 86, 100973.	15.5	133
5	The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy. <i>Eye</i> , 2022, 36, 1086-1093.	2.1	8
6	Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	10
7	Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naïve patients in the UK: DRACO study 12-month outcomes. <i>Eye</i> , 2022, 36, 64-71.	2.1	11
8	Diagnostic circulating biomarkers to detect vision-threatening diabetic retinopathy: Potential screening tool of the future?. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	12
9	Early detection of neovascular age-related macular degeneration: an economic evaluation based on data from the EDNA study. <i>British Journal of Ophthalmology</i> , 2022, 106, 1754-1761.	3.9	1
10	Multimodal Imaging Comparison of Polypoidal Choroidal Vasculopathy Between Asian and Caucasian Populations. <i>American Journal of Ophthalmology</i> , 2022, 234, 108-116.	3.3	10
11	Incidence and Risk Factors for Macular Atrophy in Acquired Vitelliform Lesions. <i>Ophthalmology Retina</i> , 2022, 6, 196-204.	2.4	5
12	Risk of bias: why measure it, and how?. <i>Eye</i> , 2022, 36, 346-348.	2.1	12
13	The Diagnostic Accuracy of Double-Layer Sign in Detection of Macular Neovascularization Secondary to Central Serous Chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2022, 236, 271-280.	3.3	8
14	Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	5
15	The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure. <i>Ophthalmology</i> , 2022, 129, 498-508.	5.2	8
16	Near infrared spectroscopy reveals instability in retinal mitochondrial metabolism and haemodynamics with blue light exposure at environmental levels. <i>Journal of Biophotonics</i> , 2022, 15, e2916.	2.3	5
17	The clinician's guide to interpreting a regression analysis. <i>Eye</i> , 2022, 36, 1715-1717.	2.1	10
18	Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy. <i>JAMA Ophthalmology</i> , 2022, 140, 143.	2.5	6

#	ARTICLE	IF	CITATIONS
19	An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. <i>Eye</i> , 2022, 36, 1154-1167.	2.1	28
20	The clinician's guide to randomized trials: interpretation. <i>Eye</i> , 2022, , .	2.1	0
21	Prevalence and risk factors for diabetic retinopathy in prediabetes in Asian Indians. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108131.	2.3	7
22	Guidelines for patient management: considerations before adoption into practice. <i>Eye</i> , 2022, , .	2.1	0
23	Evaluating a Deep Learning Diabetic Retinopathy Grading System Developed on Mydriatic Retinal Images When Applied to Non-Mydriatic Community Screening. <i>Journal of Clinical Medicine</i> , 2022, 11, 614.	2.4	8
24	Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study. <i>Health Technology Assessment</i> , 2022, 26, 1-142.	2.8	5
25	Retinal vein occlusion (RVO) guideline: executive summary. <i>Eye</i> , 2022, 36, 909-912.	2.1	29
26	Tele-Ophthalmology Versus Face-to-Face Retinal Consultation for Assessment of Diabetic Retinopathy in Diabetes Care Centers in India: A Multicenter Cross-Sectional Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 556-563.	4.4	4
27	Retinal non-perfusion in the ETDRS seven fields compared with widefield fluorescein angiography: correlation and use of extrapolation factor. <i>Retina</i> , 2022, Publish Ahead of Print, .	1.7	1
28	Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses – An Updated Review. <i>Asia-Pacific Journal of Ophthalmology</i> , 2022, 11, 247-257.	2.5	17
29	Diabetic macular ischaemia- a new therapeutic target?. <i>Progress in Retinal and Eye Research</i> , 2022, 89, 101033.	15.5	34
30	Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. <i>Advances in Therapy</i> , 2022, 39, 2701-2716.	2.9	7
31	Correlation of Optical Coherence Tomography Angiography Characteristics with Visual Function to Define Vision-Threatening Diabetic Macular Ischemia. <i>Diagnostics</i> , 2022, 12, 1050.	2.6	3
32	Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. <i>Survey of Ophthalmology</i> , 2022, 67, 1346-1363.	4.0	12
33	Artificial intelligence-based strategies to identify patient populations and advance analysis in age-related macular degeneration clinical trials. <i>Experimental Eye Research</i> , 2022, 220, 109092.	2.6	2
34	Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy. <i>Eye</i> , 2022, , .	2.1	1
35	Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2022, 140, 587.	2.5	10
36	Sensitivity analysis in clinical trials: three criteria for a valid sensitivity analysis. <i>Eye</i> , 2022, 36, 2073-2074.	2.1	6

#	ARTICLE	IF	CITATIONS
37	Prevalence of diabetic retinopathy in urban and rural India: A systematic review and meta-analysis. Indian Journal of Ophthalmology, 2022, 70, 1945.	1.1	5
38	Correlating the patterns of diabetic macular edema, optical coherence tomography biomarkers and grade of diabetic retinopathy with stage of renal disease. International Ophthalmology, 2022, 42, 3333-3343.	1.4	1
39	The Royal College of Ophthalmologists Commissioning guidelines on age macular degeneration: executive summary. Eye, 2022, 36, 2078-2083.	2.1	3
40	Living Without a Diagnosis: A Patient's Perspective on Diabetic Macular Ischemia. Ophthalmology and Therapy, 2022, 11, 1617-1628.	2.3	2
41	The Role of Neuroglobin in Retinal Hemodynamics and Metabolism: A Real-Time Study. Translational Vision Science and Technology, 2022, 11, 2.	2.2	1
42	Ten-year survival trends of neovascular age-related macular degeneration at first presentation. British Journal of Ophthalmology, 2021, 105, 1688-1695.	3.9	9
43	Need for Vitreous Surgeries in Proliferative Diabetic Retinopathy in 10-Year Follow-Up: India Retinal Disease Study Group Report No. 2. Ophthalmic Research, 2021, 64, 432-439.	1.9	7
44	Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration. Eye, 2021, 35, 409-417.	2.1	15
45	Long-term follow-up of management of choroidal neovascularisation secondary to angioid streaks with intravitreal anti-vascular endothelial growth factor. Eye, 2021, 35, 853-857.	2.1	8
46	Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study. Eye, 2021, 35, 592-600.	2.1	21
47	Drusen and pachydrusen: the definition, pathogenesis, and clinical significance. Eye, 2021, 35, 121-133.	2.1	38
48	Adaptive optics: principles and applications in ophthalmology. Eye, 2021, 35, 244-264.	2.1	33
49	Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy. Ophthalmology, 2021, 128, 561-573.	5.2	15
50	Low Luminance Visual Acuity and Low Luminance Deficit in Proliferative Diabetic Retinopathy. Journal of Clinical Medicine, 2021, 10, 358.	2.4	3
51	Impact of treatment of diabetic macular edema on visual impairment in people with diabetes mellitus in India. Indian Journal of Ophthalmology, 2021, 69, 671.	1.1	8
52	Impact on health and provision of healthcare services during the COVID-19 lockdown in India: a multicentre cross-sectional study. BMJ Open, 2021, 11, e043590.	1.9	53
53	Diabetic retinopathy screening guidelines in India: All India Ophthalmological Society diabetic retinopathy task force and Vitreoretinal Society of India Consensus Statement. Indian Journal of Ophthalmology, 2021, 69, 678.	1.1	31
54	Integrated People-Centered Eye Care: The Game Changer. , 2021, , 79-90.		0

#	ARTICLE	IF	CITATIONS
55	Detection of Diabetic Retinopathy from Ultra-Widefield Scanning Laser Ophthalmoscope Images: A Multicenter Deep Learning Analysis. <i>Ophthalmology Retina</i> , 2021, 5, 1097-1106.	2.4	36
56	Predictors of Visual Acuity Outcomes after Anti-VEGF Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion. <i>Ophthalmology Retina</i> , 2021, 5, 1115-1124.	2.4	17
57	Watching synchronous mitochondrial respiration in the retina and its instability in a mouse model of macular degeneration. <i>Scientific Reports</i> , 2021, 11, 3274.	3.3	6
58	Looking Ahead: Visual and Anatomical Endpoints in Future Trials of Diabetic Macular Ischemia. <i>Ophthalmologica</i> , 2021, 244, 451-464.	1.9	12
59	Outcomes of neovascular glaucoma in eyes presenting with moderate to good visual potential. <i>International Ophthalmology</i> , 2021, 41, 2359-2368.	1.4	8
60	Epidemiology of moderately severe and severe non-proliferative diabetic retinopathy in South West England. <i>Eye</i> , 2021, , .	2.1	2
61	Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits—a pilot study. <i>Eye</i> , 2021, , .	2.1	3
62	EARLY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS TO CONFIRM FELLOW EYE CHANGES IN ASYMMETRIC TYPE-2 MACULAR TELANGIECTASIA. <i>Retina</i> , 2021, 41, 471-479.	1.7	7
63	Associations between attainment of incentivized primary care indicators and incident sight-threatening diabetic retinopathy in England: A population-based historical cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1322-1330.	4.4	3
64	Prefilled Eylea Syringe: our recent experience. <i>Eye</i> , 2021, 35, 2083-2085.	2.1	2
65	Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. <i>Pharmacoeconomics</i> , 2021, 39, 913-927.	3.3	6
66	Associations between attainment of incentivised primary care indicators and incident diabetic retinopathy in England: a population-based historical cohort study. <i>BMC Medicine</i> , 2021, 19, 93.	5.5	8
67	Recurring themes during cataract assessment and surgery. <i>Eye</i> , 2021, 35, 2482-2498.	2.1	5
68	Indicators of Visual Prognosis in Diabetic Macular Oedema. <i>Journal of Personalized Medicine</i> , 2021, 11, 449.	2.5	12
69	Deep learning for gradability classification of handheld, non-mydratic retinal images. <i>Scientific Reports</i> , 2021, 11, 9469.	3.3	10
70	Galectins in the Pathogenesis of Common Retinal Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 687495.	3.5	3
71	Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. <i>Health Technology Assessment</i> , 2021, 25, 1-104.	2.8	1
72	Response to “Comment on “Drusen and pachydrusen: the definition, pathogenesis and clinical significance””. <i>Eye</i> , 2021, , .	2.1	0

#	ARTICLE	IF	CITATIONS
73	Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities. <i>Eye</i> , 2021, 35, 2685-2698.	2.1	35
74	Scotopic thresholds on dark-adapted chromatic perimetry in healthy aging and age-related macular degeneration. <i>Scientific Reports</i> , 2021, 11, 10349.	3.3	5
75	Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2021, 139, 501.	2.5	6
76	Reply to: "Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy". <i>Eye</i> , 2021, 35, 3448.	2.1	0
77	Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. <i>Human Mutation</i> , 2021, 42, 1139-1152.	2.5	8
78	Is immediate treatment necessary for diabetic macular edema after pars plana vitrectomy for tractional complications of proliferative diabetic retinopathy?. <i>International Ophthalmology</i> , 2021, 41, 3607-3614.	1.4	1
79	Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-196.	2.8	10
80	Development and validation of resource-driven risk prediction models for incident chronic kidney disease in type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 13654.	3.3	6
81	Microvascular changes precede visible neurodegeneration in fellow eyes of patients with asymmetric type 2 macular telangiectasia. <i>Eye</i> , 2021, , .	2.1	3
82	Ethnic Disparities in the Development of Sight-Threatening Diabetic Retinopathy in a UK Multi-Ethnic Population with Diabetes: An Observational Cohort Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 740.	2.5	9
83	Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2021, 128, 1736-1747.	5.2	17
84	Durability of anti-vascular endothelial growth factor agents in neovascular age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 540-541.	2.6	0
85	Reply. <i>Ophthalmology</i> , 2021, 128, e46-e47.	5.2	0
86	Sensitivity and specificity of pseudocolor ultrawide field imaging in comparison to wide field fundus fluorescein angiography in detecting retinal neovascularization in diabetic retinopathy. <i>Eye</i> , 2021, , .	2.1	2
87	Attendance Rate in Patients with Diabetic Macular Edema Receiving Short Messages. <i>Ophthalmology Retina</i> , 2021, 5, 1054-1056.	2.4	1
88	Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-82.	0.7	4
89	In vivo fluorescence molecular imaging of the vascular endothelial growth factor in rats with early diabetic retinopathy. <i>Biomedical Optics Express</i> , 2021, 12, 7185.	2.9	2
90	Identifying Peripheral Neuropathy in Colour Fundus Photographs Based on Deep Learning. <i>Diagnostics</i> , 2021, 11, 1943.	2.6	6

#	ARTICLE	IF	CITATIONS
91	Complex interventions to implement a diabetic retinopathy care pathway in the public health system in Kerala: the Nayanamritham study protocol. <i>BMJ Open</i> , 2021, 11, e040577.	1.9	4
92	The ORNATE India project: Building research capacity and capability to tackle the burden of diabetic retinopathy-related blindness in India. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3058.	1.1	0
93	Severity of diabetic retinopathy and its relationship with age at onset of diabetes mellitus in India: A multicentric study. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3255.	1.1	9
94	Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3076.	1.1	7
95	Bridging the valley of death between research and implementing a systematic diabetic retinopathy screening program in low- and medium-income countries. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3068.	1.1	1
96	Dysregulated Serum Lipid Metabolism Promotes the Occurrence and Development of Diabetic Retinopathy Associated With Upregulated Circulating Levels of VEGF-A, VEGF-D, and PlGF. <i>Frontiers in Medicine</i> , 2021, 8, 779413.	2.6	17
97	Cataract surgery in patients with age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2021, 56, 347.	0.7	0
98	Assessment of optical coherence tomography angiography and multifocal electroretinography in eyes with and without nonproliferative diabetic retinopathy. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3235.	1.1	4
99	Adding screening for "end organ damage" to the noncommunicable disease package in primary care. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3064.	1.1	0
100	Identification of risk factors for targeted diabetic retinopathy screening to urgently decrease the rate of blindness in people with diabetes in India. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3156.	1.1	4
101	Barriers in establishing systematic diabetic retinopathy screening through telemedicine in low- and middle-income countries. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 2987.	1.1	2
102	The blue circle and 100 years of insulin discovery. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 2920.	1.1	1
103	Burden of Diabetic Retinopathy amongst People with Diabetes Attending Primary Care in Kerala: Nayanamritham Project. <i>Journal of Clinical Medicine</i> , 2021, 10, 5903.	2.4	3
104	Complex interventions to implement a diabetic retinopathy care pathway in the public health system in Kerala: the Nayanamritham study protocol. <i>BMJ Open</i> , 2021, 11, e040577.	1.9	10
105	Intravitreal aflibercept for diabetic macular oedema: Moorfieldsâ€™ real-world 12-month visual acuity and anatomical outcomes. <i>European Journal of Ophthalmology</i> , 2020, 30, 557-562.	1.3	23
106	A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. <i>Ophthalmology</i> , 2020, 127, 377-393.	5.2	40
107	Association of Longitudinal Changes in Drusen Characteristics and Retinal Layer Volumes with Subsequent Subtype of Choroidal Neovascularisation. <i>Ophthalmic Research</i> , 2020, 63, 375-382.	1.9	6
108	Objective Evaluation of Proliferative Diabetic Retinopathy Using OCT. <i>Ophthalmology Retina</i> , 2020, 4, 164-174.	2.4	30

#	ARTICLE	IF	CITATIONS
109	An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification. <i>European Journal of Ophthalmology</i> , 2020, 30, 8-18.	1.3	70
110	Evaluating the Performance of the Indian Diabetes Risk Score in Different Ethnic Groups. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 285-300.	4.4	3
111	Exploratory Study on Visual Acuity and Patient-Perceived Visual Function in Patients with Subretinal Drusenoid Deposits. <i>Journal of Clinical Medicine</i> , 2020, 9, 2832.	2.4	3
112	Diabetic Retinopathy Environment-Wide Association Study (EWAS) in NHANES 2005â€“2008. <i>Journal of Clinical Medicine</i> , 2020, 9, 3643.	2.4	10
113	Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial. <i>Value in Health</i> , 2020, 23, 928-935.	0.3	9
114	Deep Learning-Based Segmentation and Quantification of Retinal Capillary Non-Perfusion on Ultra-Wide-Field Retinal Fluorescein Angiography. <i>Journal of Clinical Medicine</i> , 2020, 9, 2537.	2.4	15
115	Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. <i>Ophthalmology Retina</i> , 2020, 4, 1043-1046.	2.4	64
116	<p>A Review of Advancements and Evidence Gaps in Diabetic Retinopathy Screening Models</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 3285-3296.	1.8	17
117	Evaluation of real-world early response of DMO to aflibercept therapy to inform future clinical trial design of novel investigational agents. <i>Scientific Reports</i> , 2020, 10, 16499.	3.3	3
118	Long-term follow-up of a case of posterior microphthalmos (PRSS56) with hyperautofluorescent retinal pigment epithelial deposits. <i>European Journal of Ophthalmology</i> , 2020, , 112067212094975.	1.3	2
119	Differences in macular microvascular changes between eyes with central retinal vein occlusion and proliferative diabetic retinopathy. <i>Eye</i> , 2020, 35, 3170-3172.	2.1	1
120	Eplerenone for chronic central serous chorioretinopathy â€“ Authors' reply. <i>Lancet, The</i> , 2020, 396, 1557-1558.	13.7	2
121	Hydroxychloroquine hitting the headlinesâ€™ retinal considerations. <i>Eye</i> , 2020, 34, 1158-1160.	2.1	7
122	Correlation between markers of renal function and sight-threatening diabetic retinopathy in type 2 diabetes: a longitudinal study in an Indian clinic population. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001325.	2.8	23
123	The ORNATE India Project: United Kingdomâ€™India Research Collaboration to tackle visual impairment due to diabetic retinopathy. <i>Eye</i> , 2020, 34, 1279-1286.	2.1	18
124	COVID19 and ophthalmology: a brief summary of the literature. <i>Eye</i> , 2020, 34, 1200-1202.	2.1	9
125	Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. <i>Progress in Retinal and Eye Research</i> , 2020, 79, 100865.	15.5	125
126	Editorial on the consensus statement on diabetic retinopathy care pathway. <i>Eye</i> , 2020, 34, 1297-1298.	2.1	1

#	ARTICLE	IF	CITATIONS
127	Aflibercept Reduces Retinal Hemorrhages and Intravitreal Microvascular Abnormalities But Not Venous Beading. <i>Ophthalmology Retina</i> , 2020, 4, 689-694.	2.4	11
128	Optically Improved Mitochondrial Function Redeems Aged Human Visual Decline. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, e49-e52.	3.6	34
129	Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1934.	2.4	8
130	Prevalence and incidence of visual impairment in patients with proliferative diabetic retinopathy in India. <i>Scientific Reports</i> , 2020, 10, 10513.	3.3	7
131	Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2020, 395, 294-303.	13.7	134
132	Ten-year outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration. <i>Eye</i> , 2020, 34, 1888-1896.	2.1	51
133	Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. <i>Nature Genetics</i> , 2020, 52, 160-166.	21.4	192
134	Prevalence of polypoidal choroidal vasculopathy in Indian population: Risk factors, clinical and imaging characteristics. <i>PLoS ONE</i> , 2020, 15, e0231901.	2.5	3
135	Google trends as a surrogate marker of public awareness of diabetic retinopathy. <i>Eye</i> , 2020, 34, 1010-1012.	2.1	7
136	A Pilot Study Evaluating the Effects of 670 nm Photobiomodulation in Healthy Ageing and Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2020, 9, 1001.	2.4	14
137	Capacity building for universal eye health coverage in South East Asia beyond 2020. <i>Eye</i> , 2020, 34, 1262-1270.	2.1	15
138	Tackling diabetic retinopathy from the grassroots. <i>Indian Journal of Ophthalmology</i> , 2020, 68, 8.	1.1	2
139	Segmented Macular Layer Volumes from Spectral Domain Optical Coherence Tomography in 184 Adult Twins: Associations With Age and Heritability. , 2020, 61, 44.		1
140	Patient and provider perspectives on barriers to screening for diabetic retinopathy: an exploratory study from southern India. <i>BMJ Open</i> , 2020, 10, e037277.	1.9	15
141	Protocol on a multicentre statistical and economic modelling study of risk-based stratified and personalised screening for diabetes and its complications in India (SMART India). <i>BMJ Open</i> , 2020, 10, e039657.	1.9	12
142	The unmet need for better risk stratification of non-proliferative diabetic retinopathy. <i>Diabetic Medicine</i> , 2019, 36, 424-433.	2.3	36
143	Discrepancy in current central serous chorioretinopathy classification. <i>British Journal of Ophthalmology</i> , 2019, 103, 737-742.	3.9	45
144	Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer's disease are not present in diabetic Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 11386.	3.3	16

#	ARTICLE	IF	CITATIONS
145	Diagnostic Accuracy of Community-Based Diabetic Retinopathy Screening With an Offline Artificial Intelligence System on a Smartphone. <i>JAMA Ophthalmology</i> , 2019, 137, 1182.	2.5	146
146	Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). <i>Ophthalmologica</i> , 2019, 242, 123-162.	1.9	153
147	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. <i>Progress in Retinal and Eye Research</i> , 2019, 73, 100770.	15.5	276
148	Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vessels in Diabetic retinopathy (EMERALD). <i>BMJ Open</i> , 2019, 9, e027795.	1.9	7
149	Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion. <i>JAMA Ophthalmology</i> , 2019, 137, 1256.	2.5	80
150	Associations with Corneal Hysteresis in a Population Cohort. <i>Ophthalmology</i> , 2019, 126, 1500-1510.	5.2	29
151	Changes in macular drusen parameters preceding the development of neovascular age-related macular degeneration. <i>Eye</i> , 2019, 33, 910-916.	2.1	11
152	Baseline Predictive Factors in Diabetic Macular Edema Treated With Anti-vascular Endothelial Growth Factor Therapy. <i>JAMA Ophthalmology</i> , 2019, 137, 390.	2.5	0
153	Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000226.	1.6	2
154	The Relationship Between Retinal Vessel Oxygenation and Spatial Distribution of Retinal Nonperfusion in Retinal Vascular Diseases. , 2019, 60, 2083.		3
155	Artificial intelligence using deep learning to screen for referable and vision-threatening diabetic retinopathy in Africa: a clinical validation study. <i>The Lancet Digital Health</i> , 2019, 1, e35-e44.	12.3	205
156	A hidden footprint: embryological origins of age related macular degeneration. <i>Eye</i> , 2019, 33, 1675-1676.	2.1	0
157	SUBCLINICAL MACULAR CHANGES AND DISEASE LATERALITY IN PEDIATRIC COATS DISEASE DETERMINED BY QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. <i>Retina</i> , 2019, 39, 2392-2398.	1.7	15
158	Fundus Fluorescein Angiography. , 2019, , 83-96.		0
159	Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2019, 137, 626.	2.5	55
160	Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept. <i>Ophthalmology Retina</i> , 2019, 3, 567-575.	2.4	19
161	Complement factor H regulates retinal development and its absence may establish a footprint for age related macular degeneration. <i>Scientific Reports</i> , 2019, 9, 1082.	3.3	29
162	Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 122.	1.6	22

#	ARTICLE	IF	CITATIONS
163	Myocilin Mutations in Patients With Normal-Tension Glaucoma. <i>JAMA Ophthalmology</i> , 2019, 137, 559.	2.5	17
164	Diagnostic algorithm utilising multimodal imaging including optical coherence tomography angiography for the detection of myopic choroidal neovascularisation. <i>Eye</i> , 2019, 33, 1111-1118.	2.1	10
165	Deep Learning for Prediction of AMD Progression: A Pilot Study. , 2019, 60, 712.		73
166	Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab. <i>Eye</i> , 2019, 33, 930-937.	2.1	12
167	IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107840.	2.8	202
168	PIN156 INTRAVITREAL THERAPY WITH RANIBIZUMAB VS AFLIBERCEPT VS BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION: A WITHIN TRIAL COST-UTILITY ANALYSIS. <i>Value in Health</i> , 2019, 22, S664.	0.3	1
169	The Detection and Partial Localisation of Heteroplasmic Mutations in the Mitochondrial Genome of Patients with Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6259.	4.1	2
170	Anti-Vascular Endothelial Growth Factor Therapy and Cardiovascular Disease Risk. <i>Frontiers in Diabetes</i> , 2019, , 100-105.	0.4	0
171	Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. <i>Eye</i> , 2019, 33, 295-303.	2.1	13
172	Fundus photograph-based deep learning algorithms in detecting diabetic retinopathy. <i>Eye</i> , 2019, 33, 97-109.	2.1	109
173	Changes in volume of various retinal layers over time in early and intermediate age-related macular degeneration. <i>Eye</i> , 2019, 33, 428-434.	2.1	46
174	Living with Geographic Atrophy: An Ethnographic Study. <i>Ophthalmology and Therapy</i> , 2019, 8, 115-124.	2.3	22
175	Lightmasks that prevent dark adaptation for non-central diabetic macular oedema: the CLEOPATRA RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-78.	0.7	0
176	Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2018, 96, e835-e839.	1.1	25
177	Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). <i>Ophthalmology</i> , 2018, 125, 691-700.	5.2	84
178	Welcome message from the new Editor-in-Chief. <i>Eye</i> , 2018, 32, 49-49.	2.1	0
179	Prevalence of diabetic retinopathy and visual impairment in patients with diabetes mellitus in Zambia through the implementation of a mobile diabetic retinopathy screening project in the Copperbelt province: a cross-sectional study. <i>Eye</i> , 2018, 32, 1201-1208.	2.1	22
180	Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study. <i>American Journal of Ophthalmology</i> , 2018, 190, 1-8.	3.3	38

#	ARTICLE	IF	CITATIONS
181	Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 382-391.	11.4	25
182	Quantifying Retinal Area in Ultra-Widefield Imaging Using a 3-Dimensional Printed Eye Model. <i>Ophthalmology Retina</i> , 2018, 2, 65-71.	2.4	13
183	PSS5 - VISION-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH INTRAVITREAL AFLIBERCEPT: THE AQUA STUDY. <i>Value in Health</i> , 2018, 21, S422-S423.	0.3	0
184	Dietary change for macular health of older people: Eating for Eye Health, a pilot community kitchens intervention. <i>Lancet</i> , 2018, 392, S37.	13.7	2
185	Advances in the diagnosis of sickle cell retinopathy. <i>Expert Review of Ophthalmology</i> , 2018, 13, 267-272.	0.6	0
186	Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy. , 2018, 59, 4277.		29
187	Age-related Macular Degeneration detection using deep convolutional neural network. <i>Future Generation Computer Systems</i> , 2018, 87, 127-135.	7.5	109
188	Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema. <i>PLoS ONE</i> , 2018, 13, e0199693.	2.5	8
189	Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. <i>Ophthalmology and Therapy</i> , 2018, 7, 361-368.	2.3	37
190	Vision Preference Value Scale and Patient Preferences in Choosing Therapy for Symptomatic Vitreomacular Interface Abnormality. <i>JAMA Ophthalmology</i> , 2018, 136, 658.	2.5	1
191	The past is the prologue to the future. <i>Eye</i> , 2018, 32, 847-848.	2.1	0
192	Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes. <i>Eye</i> , 2018, 32, 1523-1529.	2.1	4
193	Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT. <i>Efficacy and Mechanism Evaluation</i> , 2018, 5, 1-112.	0.7	9
194	Normative Data on Foveal Avascular Zone Dimensions in Four Macular Vascular Layers. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018, 49, 580-586.	0.7	4
195	Localization of Paracentral Acute Middle Maculopathy Using Optical Coherence Tomography Angiography. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018, 49, 619-624.	0.7	2
196	Double-layer sign on spectral domain optical coherence tomography in pachychoroid spectrum disease. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 1796.	1.1	28
197	Treatment Modalities for Idiopathic Macular Telangiectasia: An Evidence-Based Systematic Review of the Literature. <i>Seminars in Ophthalmology</i> , 2017, 32, 384-394.	1.6	13
198	Reply. <i>American Journal of Ophthalmology</i> , 2017, 174, 186.	3.3	0

#	ARTICLE	IF	CITATIONS
199	Segmentation of optic disc, fovea and retinal vasculature using a single convolutional neural network. <i>Journal of Computational Science</i> , 2017, 20, 70-79.	2.9	196
200	Retinal angiomatous proliferation. <i>Survey of Ophthalmology</i> , 2017, 62, 462-492.	4.0	59
201	Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. <i>Lancet, The</i> , 2017, 389, 2193-2203.	13.7	279
202	Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema. <i>Eye</i> , 2017, 31, 1358-1364.	2.1	4
203	Clinical Phenotypes of Poppers Maculopathy and Their Links to Visual and Anatomic Recovery. <i>Ophthalmology</i> , 2017, 124, 1425-1427.	5.2	19
204	Aging retinal function is improved by near infrared light (670Ånm) that is associated with corrected mitochondrial decline. <i>Neurobiology of Aging</i> , 2017, 52, 66-70.	3.1	34
205	Diagnosis of retinal health in digital fundus images using continuous wavelet transform (CWT) and entropies. <i>Computers in Biology and Medicine</i> , 2017, 84, 89-97.	7.0	59
206	Reply. <i>American Journal of Ophthalmology</i> , 2017, 174, 176.	3.3	0
207	Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion. <i>American Journal of Ophthalmology</i> , 2017, 182, 118-125.	3.3	34
208	Automated segmentation of exudates, haemorrhages, microaneurysms using single convolutional neural network. <i>Information Sciences</i> , 2017, 420, 66-76.	6.9	210
209	Retinal Oximetry Differences Between Optic Disc Collateral Vessels and New Vessels. <i>JAMA Ophthalmology</i> , 2017, 135, 1003.	2.5	3
210	Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2211.	7.4	1,442
211	Intravitreal aflibercept for proliferative diabetic retinopathy – Authors' reply. <i>Lancet, The</i> , 2017, 390, 2141-2142.	13.7	0
212	Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration. <i>Eye</i> , 2017, 31, 1613-1620.	2.1	11
213	Identification of time point to best define –sub-optimal response–™ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data. <i>Eye</i> , 2017, 31, 1594-1599.	2.1	22
214	Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting. <i>American Journal of Ophthalmology</i> , 2017, 174, 160-168.	3.3	43
215	The effect of vitreous on proliferative diabetic retinopathy and the response to panretinal photocoagulation. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 423-424.	1.9	0
216	Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis. <i>Ophthalmic Research</i> , 2017, 58, 49-55.	1.9	5

#	ARTICLE	IF	CITATIONS
217	Detection of Early Loss of Color Vision in Age-Related Macular Degeneration " With Emphasis on Drusen and Reticular Pseudodrusen. , 2017, 58, BIO247.		21
218	Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema. Patient Preference and Adherence, 2017, Volume 11, 579-586.	1.8	10
219	Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clinical Ophthalmology, 2017, Volume 11, 1957-1966.	1.8	17
220	Model for Risk-Based Screening of Diabetic Retinopathy in People With Newly-Diagnosed Type 2 Diabetes Mellitus. , 2017, 58, BIO99.		16
221	Central Serous Chorioretinopathy. , 2017, , 139-159.		0
222	Retinal Biochemistry, Physiology and Cell Biology. Developments in Ophthalmology, 2016, 55, 18-27.	0.1	2
223	Relevance of Retinal Thickness Changes in the OCT Inner and Outer Rings to Predict Progression to Clinical Macular Edema: An Attempt of Composite Grading of Macular Edema. Ophthalmic Research, 2016, 55, 19-25.	1.9	5
224	Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting. Patient Preference and Adherence, 2016, 10, 949.	1.8	12
225	A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clinical Ophthalmology, 2016, 10, 87.	1.8	27
226	Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clinical Ophthalmology, 2016, 10, 1103.	1.8	61
227	An exploratory study evaluating the effects of macular carotenoid supplementation in various retinal diseases. Clinical Ophthalmology, 2016, 10, 835.	1.8	11
228	Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clinical Ophthalmology, 2016, 10, 939.	1.8	76
229	Posterior Segment Distortion in Ultra-Widefield Imaging Compared to Conventional Modalities. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 644-651.	0.7	7
230	Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. Translational Vision Science and Technology, 2016, 5, 2.	2.2	89
231	Video Angiography of Cilioretinal Artery Infarction in Central Retinal Vein Occlusion. Retina, 2016, 36, e33-e35.	1.7	2
232	PREVALENCE OF THE COMPLEMENT FACTOR H AND GSTM1 GENES POLYMORPHISMS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2016, 36, 402-407.	1.7	37
233	Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. British Journal of Ophthalmology, 2016, 100, 1623-1628.	3.9	104
234	HYPERREFLECTIVE FOCI AS AN INDEPENDENT VISUAL OUTCOME PREDICTOR IN MACULAR EDEMA DUE TO RETINAL VASCULAR DISEASES TREATED WITH INTRAVITREAL DEXAMETHASONE OR RANIBIZUMAB. Retina, 2016, 36, 2319-2328.	1.7	73

#	ARTICLE	IF	CITATIONS
235	Reliability and Convergent Validity of The Nei Vfq-25 with and Without Near and Distance Activity Appendix Items In Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD). Value in Health, 2016, 19, A572.	0.3	0
236	Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1247-1256.	1.9	28
237	Perspectives on reticular pseudodrusen in age-related macular degeneration. Survey of Ophthalmology, 2016, 61, 521-537.	4.0	72
238	Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye, 2016, 30, 1063-1071.	2.1	40
239	Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting. American Journal of Ophthalmology, 2016, 172, 51-57.	3.3	74
240	Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema. Advances in Therapy, 2016, 33, 597-609.	2.9	2
241	Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept. Ophthalmology, 2016, 123, 1762-1770.	5.2	22
242	Reply: "Myopic foveoschisis: an ectatic retinopathy, not a schisis"™. Eye, 2016, 30, 329-330.	2.1	0
243	First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 337-343.	5.2	85
244	Spare the rods and spoil the retina: revisited. Eye, 2016, 30, 189-192.	2.1	22
245	A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetologica, 2016, 53, 643-650.	2.5	53
246	Prediction of regression of retinal neovascularisation after panretinal photocoagulation for proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1715-1721.	1.9	8
247	Reply. American Journal of Ophthalmology, 2016, 161, 220-221.	3.3	2
248	A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). British Journal of Ophthalmology, 2016, 100, 802-807.	3.9	20
249	Associations between Retinal Markers of Microvascular Disease and Cognitive Impairment in Newly Diagnosed Type 2 Diabetes Mellitus: A Case Control Study. PLoS ONE, 2016, 11, e0147160.	2.5	16
250	Validation of Concentric Rings Method as a Topographic Measure of Retinal Nonperfusion in Ultra-Widefield Fluorescein Angiography. American Journal of Ophthalmology, 2015, 160, 1217-1225.e2.	3.3	25
251	Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2. , 2015, 56, 5698.		22
252	Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration. PLoS ONE, 2015, 10, e0129361.	2.5	59

#	ARTICLE	IF	CITATIONS
253	Diabetes Complications at Presentation and One Year by Glycated Haemoglobin at Diagnosis in a Multiethnic and Diverse Socioeconomic Population: Results from the South London Diabetes Study. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-8.	2.3	6
254	Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-9.	2.3	38
255	Diagnostic accuracy of disorganization of the retinal inner layers in detecting macular capillary non-perfusion in diabetic retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2015, 43, 735-741.	2.6	72
256	One-Year Progression of Diabetic Subclinical Macular Edema in Eyes with Mild Nonproliferative Diabetic Retinopathy: Location of the Increase in Retinal Thickness. <i>Ophthalmic Research</i> , 2015, 54, 118-123.	1.9	13
257	Spectral domain optical coherence tomography in patients with sickle cell disease. <i>British Journal of Ophthalmology</i> , 2015, 99, 967-972.	3.9	74
258	Age, Sex, and Ethnic Variations in Inner and Outer Retinal and Choroidal Thickness on Spectral-Domain Optical Coherence Tomography. <i>American Journal of Ophthalmology</i> , 2015, 160, 1034-1043.e1.	3.3	66
259	Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2015, 99, 220-226.	3.9	474
260	Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment. <i>Ophthalmology</i> , 2015, 122, 1811-1819.	5.2	41
261	Defining response to anti-VEGF therapies in neovascular AMD. <i>Eye</i> , 2015, 29, 721-731.	2.1	214
262	Myopic foveoschisis: a clinical review. <i>Eye</i> , 2015, 29, 593-601.	2.1	75
263	Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. <i>BMJ Open</i> , 2015, 5, e008405.	1.9	23
264	The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. <i>Eye</i> , 2015, 29, 1633-1638.	2.1	61
265	Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. <i>Eye</i> , 2015, 29, S1-S11.	2.1	22
266	Altered circulating mitochondrial DNA and increased inflammation in patients with diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 257-265.	2.8	61
267	A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). <i>Eye</i> , 2015, 29, 1603-1612.	2.1	32
268	Retinal Layer Location of Increased Retinal Thickness in Eyes with Subclinical and Clinical Macular Edema in Diabetes Type 2. <i>Ophthalmic Research</i> , 2015, 54, 112-117.	1.9	45
269	Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1685-1697.	3.1	16
270	Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study. <i>PLoS ONE</i> , 2015, 10, e0128403.	2.5	14

#	ARTICLE	IF	CITATIONS
271	Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. <i>Health Technology Assessment</i> , 2015, 19, 1-116.	2.8	90
272	An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema. <i>Clinical Ophthalmology</i> , 2014, 8, 1565.	1.8	10
273	Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1). <i>Eye</i> , 2014, 28, 318-326.	2.1	33
274	Normative spectral domain optical coherence tomography data on macular and retinal nerve fiber layer thickness in Indians. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 316.	1.1	51
275	Changes in Detection of Retinopathy in Type 2 Diabetes in the First 4 Years of a Population-Based Diabetic Eye Screening Program: Retrospective Cohort Study. <i>Diabetes Care</i> 2013;36:2663-2669. <i>Diabetes Care</i> , 2014, 37, 2063.3-2063.	8.6	0
276	Correlation of Fundus Fluorescein Angiography and Spectral-Domain Optical Coherence Tomography in Identification of Membrane Subtypes in Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2014, 231, 153-159.	1.9	13
277	A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 458.	1.6	17
278	A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (the LUCIDATE Study). <i>American Journal of Ophthalmology</i> , 2014, 157, 960-970.e2.	3.3	75
279	Photodynamic therapy for central serous chorioretinopathy. <i>Eye</i> , 2014, 28, 944-957.	2.1	74
280	Differences in the topographic profiles of retinal thickening in eyes with and without serous macular detachment associated with diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2014, 98, 182-187.	3.9	16
281	Factors Affecting Reading Speed in Patients with Diabetic Macular Edema Treated with Laser Photocoagulation. <i>PLoS ONE</i> , 2014, 9, e105696.	2.5	28
282	Non-attendance at diabetic eye screening and risk of sight-threatening diabetic retinopathy: a population-based cohort study. <i>Diabetologia</i> , 2013, 56, 2187-2193.	6.3	39
283	The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D). <i>Diabetologia</i> , 2013, 56, 1272-1281.	6.3	61
284	The Relationship Between Diabetic Retinopathy and Cognitive Impairment. <i>Diabetes Care</i> , 2013, 36, 3177-3186.	8.6	43
285	Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. <i>Diabetic Medicine</i> , 2013, 30, 640-650.	2.3	209
286	Predictive Value of Spectral-Domain Optical Coherence Tomography Features in Assessment of Visual Prognosis in Eyes With Neovascular Age-Related Macular Degeneration Treated With Ranibizumab. <i>American Journal of Ophthalmology</i> , 2013, 155, 720-726.e1.	3.3	38
287	Ranibizumab in Myopic Choroidal Neovascularization: The 12-Month Results from the REPAIR Study. <i>Ophthalmology</i> , 2013, 120, 1944-1945.e1.	5.2	94
288	Age-related Macular Degeneration and Modification of Systemic Complement Factor H Production Through Liver Transplantation. <i>Ophthalmology</i> , 2013, 120, 1612-1618.	5.2	39

#	ARTICLE	IF	CITATIONS
289	Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. <i>Circulation Research</i> , 2013, 112, 595-600.	4.5	366
290	Agreement between Time-Domain and Spectral-Domain Optical Coherence Tomography in the Assessment of Macular Thickness in Patients with Idiopathic Macular Telangiectasia Type 2. <i>Ophthalmologica</i> , 2013, 230, 144-150.	1.9	7
291	Optimisation of an automated drusen-quantifying software for the analysis of drusen distribution in patients with age-related macular degeneration. <i>Eye</i> , 2013, 27, 554-560.	2.1	4
292	Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. <i>Eye</i> , 2013, 27, 709-715.	2.1	45
293	Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). <i>Eye</i> , 2013, 27, 959-963.	2.1	22
294	Giant Cell Arteritis Presenting as Choroidal Infarction. <i>Case Reports in Ophthalmological Medicine</i> , 2013, 2013, 1-3.	0.5	6
295	Sensitivity and specificity of time-domain versus spectral-domain optical coherence tomography in diabetic macular edema. <i>Indian Journal of Ophthalmology</i> , 2013, 61, 208.	1.1	6
296	Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4). <i>PLoS ONE</i> , 2013, 8, e72755.	2.5	17
297	What is new in the management of wet age-related macular degeneration?. <i>British Medical Bulletin</i> , 2013, 105, 201-211.	6.9	14
298	Three-Year Visual Outcome and Injection Frequency of Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2013, 230, 27-33.	1.9	16
299	Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT) Tj ETQq1 1 0.784314 rgBT /Overlo 3.9 53	3.9	53
300	Changes in Detection of Retinopathy in Type 2 Diabetes in the First 4 Years of a Population-Based Diabetic Eye Screening Program. <i>Diabetes Care</i> , 2013, 36, 2663-2669.	8.6	23
301	OP90â€¦Non-Attendance at Diabetes Eye Screening and Risk of Sight-Threatening Diabetic Retinopathy: Population-based Cohort Study. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, A42.1-A42.	3.7	0
302	Epidemiology and Aetiopathogenesis of Age-Related Macular Degeneration. , 2013, , 41-62.		0
303	Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration. <i>Eye</i> , 2012, 26, 389-393.	2.1	9
304	Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. <i>The Cochrane Library</i> , 2012, , CD004239.	2.8	42
305	Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema. <i>Expert Review of Medical Devices</i> , 2012, 9, 189-197.	2.8	27
306	Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. <i>Eye</i> , 2012, 26, 576-582.	2.1	53

#	ARTICLE	IF	CITATIONS
307	Retinal Vascular Calibre, Geometry and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus. <i>Ophthalmologica</i> , 2012, 228, 84-92.	1.9	51
308	Local and not systemic factor H production dictates risk of age-related macular degeneration in liver transplant recipients. <i>Immunobiology</i> , 2012, 217, 1182-1183.	1.9	0
309	Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: The DRIVE UK Study. <i>Eye</i> , 2012, 26, 510-516.	2.1	75
310	Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide Perspective. <i>Survey of Ophthalmology</i> , 2012, 57, 347-370.	4.0	299
311	Determinants of Fixation in Eyes With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab. <i>American Journal of Ophthalmology</i> , 2012, 153, 490-496.e1.	3.3	8
312	A systematic review of the association of diabetic retinopathy and cognitive impairment in people with Type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 101-110.	2.8	40
313	The pathogenesis of early retinal changes of diabetic retinopathy. <i>Documenta Ophthalmologica</i> , 2012, 124, 15-26.	2.2	69
314	Ethnic Variations in the Prevalence of Diabetic Retinopathy in People with Diabetes Attending Screening in the United Kingdom (DRIVE UK). <i>PLoS ONE</i> , 2012, 7, e32182.	2.5	113
315	Ethnic Variation in the Prevalence of Visual Impairment in People Attending Diabetic Retinopathy Screening in the United Kingdom (DRIVE UK). <i>PLoS ONE</i> , 2012, 7, e39608.	2.5	40
316	Unintentional Retinal Displacement. <i>Ophthalmology</i> , 2011, 118, 603-603.e2.	5.2	1
317	Treatment of proliferative diabetic retinopathy with anti-VEGF agents. <i>Acta Ophthalmologica</i> , 2011, 89, 405-411.	1.1	89
318	Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab. <i>Eye</i> , 2011, 25, 149-153.	2.1	15
319	Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. <i>Clinical and Experimental Ophthalmology</i> , 2011, 39, no-no.	2.6	23
320	Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab. <i>Eye</i> , 2011, 25, 1612-1616.	2.1	8
321	Five-year visual outcome following laser photocoagulation of diabetic macular oedema. <i>Eye</i> , 2011, 25, 850-859.	2.1	9
322	Regression of early diabetic macular oedema is associated with prevention of dark adaptation. <i>Eye</i> , 2011, 25, 1546-1554.	2.1	44
323	Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2011, 95, 386-390.	3.9	48
324	A Pilot Study on the Combination Treatment of Reduced-Fluence Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2011, 225, 200-206.	1.9	15

#	ARTICLE	IF	CITATIONS
325	Qualitative and quantitative OCT response of diffuse diabetic macular oedema to macular laser photocoagulation. <i>Eye</i> , 2011, 25, 901-908.	2.1	12
326	Hypoxia and Oxidative Stress in the Causation of Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2011, 7, 291-304.	1.3	160
327	Loss of chromatic sensitivity in AMD and diabetes: a comparative study. <i>Ophthalmic and Physiological Optics</i> , 2010, 30, 705-716.	2.0	51
328	Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. <i>Eye</i> , 2010, 24, 203-213.	2.1	23
329	Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. <i>Eye</i> , 2010, 24, 816-824.	2.1	38
330	Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience. <i>Eye</i> , 2010, 24, 793-798.	2.1	10
331	Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy. <i>Eye</i> , 2010, 24, 1018-1023.	2.1	5
332	Socio-economic and ethnic inequalities in diabetes retinal screening. <i>Diabetic Medicine</i> , 2010, 27, 282-288.	2.3	64
333	Retinal biochemistry, physiology, and cell biology. , 2010, , 15-22.		1
334	Family Practices' Achievement of Diabetes Quality of Care Targets and Risk of Screen-Detected Diabetic Retinopathy. <i>PLoS ONE</i> , 2010, 5, e10424.	2.5	4
335	Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases. <i>Clinical Ophthalmology</i> , 2010, 4, 913.	1.8	1
336	Autofluorescence and high-definition optical coherence tomography of retinal artery occlusions. <i>Clinical Ophthalmology</i> , 2010, 4, 1159.	1.8	17
337	Anti-vascular endothelial growth factor agents for diabetic maculopathy. <i>British Journal of Ophthalmology</i> , 2010, 94, 821-826.	3.9	21
338	Current treatment options for retinal angiomatous proliferans (RAP). <i>British Journal of Ophthalmology</i> , 2010, 94, 672-677.	3.9	29
339	Sickle Cell Disease and the Eye: Old and New Concepts. <i>Survey of Ophthalmology</i> , 2010, 55, 359-377.	4.0	119
340	Micropulsed Diode Laser Therapy: Evolution and Clinical Applications. <i>Survey of Ophthalmology</i> , 2010, 55, 516-530.	4.0	108
341	Intravitreal bevacizumab (AVASTIN®) in the treatment of diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2010, 88, 0-0.	1.1	0
342	Ocular neovascularization: potential for the angiotensin/Tie-2 pathway. <i>Expert Review of Ophthalmology</i> , 2009, 4, 65-78.	0.6	1

#	ARTICLE	IF	CITATIONS
343	Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2009, 93, 1341-1344.	3.9	163
344	Micropulse diode laser photocoagulation for central serous chorioâ€retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2009, 37, 801-805.	2.6	48
345	Outcome following ranibizimab therapy for neovascular age related macular degeneration in patients with poor, intermediate and good vision. <i>Acta Ophthalmologica</i> , 2009, 87, 0-0.	1.1	0
346	Visual function vs quality of life assessment in patients with laser-treated diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2009, 87, 0-0.	1.1	0
347	The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study. <i>BMC Ophthalmology</i> , 2008, 8, 15.	1.4	18
348	A new phenotype of macular dystrophy associated with a mitochondrial A3243G mutation. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 92-93.	2.6	3
349	Clinical Course and Treatment Outcomes of Sorsby Fundus Dystrophy. <i>American Journal of Ophthalmology</i> , 2008, 146, 228-234.e2.	3.3	44
350	Choroidal neovascularisation in children. <i>British Journal of Ophthalmology</i> , 2008, 92, 451-454.	3.9	39
351	Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2008, 92, 795-799.	3.9	27
352	POSTERIOR HYALOID CHANGES FOLLOWING INTRAVITREAL TRIAMCINOLONE AND MACULAR LASER FOR DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2008, 28, 1435-1442.	1.7	30
353	Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK. <i>Clinical Ophthalmology</i> , 2008, 2, 347.	1.8	5
354	Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2008, 2, 339.	1.8	6
355	Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. <i>Eye</i> , 2008, 22, 855-859.	2.1	27
356	Estimation of Systemic Complement C3 Activity in Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2007, 125, 515.	2.4	82
357	Pulsatile ocular blood flow in asymmetric age-related macular degeneration. <i>Eye</i> , 2007, 21, 506-511.	2.1	11
358	Blood pressure control in type II diabetics with diabetic retinopathy. <i>Eye</i> , 2007, 21, 708-711.	2.1	15
359	Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration. <i>Eye</i> , 2007, 21, 1511-1515.	2.1	79
360	Techniques that alter the concentration of intravitreal triamcinolone: author's reply. <i>Acta Ophthalmologica</i> , 2007, 85, 234-235.	0.3	0

#	ARTICLE	IF	CITATIONS
361	Digital Voice Signature: the future of consent?. Clinical and Experimental Ophthalmology, 2007, 35, 297-297.	2.6	3
362	Hughes syndrome. Clinical and Experimental Ophthalmology, 2007, 35, 496-498.	2.6	3
363	Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. Clinical and Experimental Ophthalmology, 2007, 35, 640-644.	2.6	76
364	Tomographic assessment of therapeutic response to uveitic macular oedema. Clinical and Experimental Ophthalmology, 2007, 35, 719-723.	2.6	43
365	Inflammatory Vascular Disease. , 2007, , 613-687.		1
366	Intravitreal steroids in the management of macular oedema. Acta Ophthalmologica, 2006, 84, 722-733.	0.3	64
367	Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration?. Eye, 2006, 20, 43-45.	2.1	12
368	Second eye of patients with unilateral neovascular age-related macular degeneration: Caucasians vs Chinese. Eye, 2006, 20, 923-926.	2.1	11
369	The complement system and age-related macular degeneration. Eye, 2006, 20, 867-872.	2.1	55
370	Homonymous hemianopia and exotropia: an important management issue. Eye, 2006, 20, 1402-1404.	2.1	8
371	Changing from Snellen to LogMAR: debate or delay?. Clinical and Experimental Ophthalmology, 2006, 34, 6-8.	2.6	47
372	The role of photodynamic therapy in ophthalmology. British Journal of Hospital Medicine (London,) Tj ETQq0 0 0 rgBT_/Overlock 10 Tf 50	0.5	1
373	Photodynamic therapy for age-related macular degeneration. Eye, 2005, 19, 1027-1028.	2.1	0
374	Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease?. Clinical and Experimental Ophthalmology, 2005, 33, 518-523.	2.6	49
375	Why is the moon white?. Clinical and Experimental Ophthalmology, 2005, 33, 571-572.	2.6	1
376	Serum Elastin-Derived Peptides in Age-Related Macular Degeneration. , 2005, 46, 3046.		45
377	Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. British Journal of Ophthalmology, 2005, 89, 1420-1422.	3.9	66
378	Proportion of treatable subtypes of choroidal neovascular membranes in age-related macular degeneration. International Congress Series, 2005, 1282, 312-316.	0.2	0

#	ARTICLE	IF	CITATIONS
379	Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. , 2004, , CD004239.		20
380	Perspectives from clinical trials: is geographic atrophy one disease?. Eye, 0, , .	2.1	2